Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2018

View Archived Issues

Loan supports Forendo's development of endometriosis therapies

Promising in vitro and in vivo results for novel 5-HT4 receptor agonist DSP-6952

ArQule describes novel tyrosine-protein kinase BTK inhibitors

New farnesoid X receptor agonists patented by Ardelyx

Eli Lilly identifies novel beta-secretase 1 inhibitors

NeuPharma identifies novel BTK and EGFR inhibitors

New phase I trial studies safety of GamEMab in healthy volunteers for emergency prevention of Ebola

Merck Sharp & Dohme initiates phase III trial of gefapixant in adults with chronic cough

Serum amyloid A-1 protein useful for diagnosing spontaneous bacterial peritonitis

FDA grants QIDP designation to APX-001 for treatment of cryptococcosis

Knight Therapeutics gains rights to commercialize tenapanor in Canada

FDA grants orphan drug designation to Cellectar's CLR-131 for neuroblastoma

FDA grants fast track designation to nintedanib for SSc-ILD

Cidara reports phase II topline data on antifungal rezafungin

Pfizer presents PF-06855800, a novel PRMT5 inhibitor for cancer

Expanded indication accepted in E.U. for Spiriva Respimat

PAT-DX1 demonstrates efficacy in animal model of glioblastoma

Heron reports topline data from EPOCH1 and EPOCH2 phase III studies of HTX-011

MRTX-1519 identified as potent, orally available LSD1 inhibitor

PANORAMA trial of Eylea meets 24-week primary endpoint

FDA grants priority review to Xtandi sNDA for nonmetastatic CRPC

Motif Bio revises timeline for iclaprim NDA submission

Genentech reports data from phase III IMpower131 study of Tecentriq in NSCLC

First-in-human use of K1-70 shows value of blocking TSH-R for Graves' ophthalmopathy

New phase I study explores CYT-001 for adjuvant immunotherapy in hepatocellular carcinoma

Suven Life Sciences patents new muscarinic M1 receptor PAMs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...